{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:00:37Z","timestamp":1761897637880,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.leukres.2021.106757","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T01:58:14Z","timestamp":1637891894000},"page":"106757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T"],"prefix":"10.1016","volume":"112","author":[{"given":"J.","family":"Kaivers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rautenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2021.106757_bib0005","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"124","article-title":"Acute myeloid leukaemia with myelodysplasia-related changes","author":"Arber DA Brunning","year":"2008"},{"key":"10.1016\/j.leukres.2021.106757_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2021.106757_bib0015","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351(cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2021.106757_bib0020","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"88","article-title":"Acute myeloid leukemia with multilineage dysplasia","author":"Brunning","year":"2001"},{"issue":"July (1)","key":"10.1016\/j.leukres.2021.106757_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1309\/AJCP58RSMFRHLHHH","article-title":"Acute myeloid leukemia with myelodysplasia-related changes","volume":"144","author":"Vardiman","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2021.106757_bib0030","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2008-10-182782","article-title":"Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system","volume":"113","author":"Weinberg","year":"2009","journal-title":"Blood"},{"issue":"August (8)","key":"10.1016\/j.leukres.2021.106757_bib0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/genes11080845","article-title":"AML with myelodysplasia-related changes: development, challenges, and treatment advances","volume":"11","author":"Koenig","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.leukres.2021.106757_bib0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3343\/alm.2019.39.3.311","article-title":"Reclassification of acute myeloid leukemia according to the 2016 WHO classification","volume":"39","author":"Jung","year":"2019","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.leukres.2021.106757_bib0045","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1309\/EM7KCQR4GLMHRCX4","article-title":"Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival","volume":"119","author":"Arber","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2021.106757_bib0050","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood-2007-08-101162","article-title":"MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients","volume":"111","author":"Wandt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106757_bib0055","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","volume":"116","author":"Miesner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106757_bib0060","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00277-014-2100-6","article-title":"Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1","volume":"93","author":"Rozman","year":"2014","journal-title":"Ann. Hematol."},{"issue":"August","key":"10.1016\/j.leukres.2021.106757_bib0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2018.06.012","article-title":"Morphologic dysplasia in Myelodysplastic Syndromes: how accurate are morphologists?","volume":"71","author":"Bennett","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2021.106757_bib0070","first-page":"E22","article-title":"Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN intermediate-risk AML patients","volume":"90","author":"Devillier","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2021.106757_bib0075","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/modpathol.2015.55","article-title":"Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia","volume":"28","author":"Weinberg","year":"2015","journal-title":"Mod. Pathol."},{"issue":"April (5)","key":"10.1016\/j.leukres.2021.106757_bib0080","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/ajcp\/aqz206","article-title":"Genetic factors in acute myeloid leukemia with myelodysplasia-related changes","volume":"153","author":"Fang","year":"2020","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2021.106757_bib0085","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.25769","article-title":"Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy","volume":"95","author":"Montalban\u2010Bravo","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"January (4)","key":"10.1016\/j.leukres.2021.106757_bib0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"February (7)","key":"10.1016\/j.leukres.2021.106757_bib0095","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:10Z","timestamp":1758934930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621017586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":19,"alternative-id":["S0145212621017586"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106757","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106757"}}